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Abstract
Bradavidin is a homotetrameric biotin-binding protein from Bradyrhizobium japonicum, a nitrogen fixing and root nodule-
forming symbiotic bacterium of the soybean. Wild-type (wt) bradavidin has 138 amino acid residues, whereas the C-
terminally truncated core-bradavidin has only 118 residues. We have solved the X-ray structure of wt bradavidin and found
that the C-terminal amino acids of each subunit were uniquely bound to the biotin-binding pocket of an adjacent subunit.
The biotin-binding pocket occupying peptide (SEKLSNTK) was named ‘‘Brad-tag’’ and it serves as an intrinsic stabilizing
ligand in wt bradavidin. The binding of Brad-tag to core-bradavidin was analysed by isothermal titration calorimetry and a
binding affinity of ,25 mM was measured. In order to study the potential of Brad-tag, a green fluorescent protein tagged
with Brad-tag was prepared and successfully concentrated from a bacterial cell lysate using core-bradavidin-functionalized
Sepharose resin.
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Introduction
Chicken egg-white avidin and its eukaryotic and prokaryotic
homologs, known collectively as avidins, are proteins that have
extreme affinity towards D-biotin (Kd ,10–15 M for chicken
avidin) [1–3]. Eukaryotic avidins exist in the eggs of e.g. birds,
reptilia and amphibians [4–7], whereas prokaryotic avidins have
been isolated from a few bacterial species: Streptomyces avidinii
(streptavidin) [8], Bradyrhizobium japonicum (bradavidin and brada-
vidin II) [9,10], Rhizobium etli (rhizavidin) [11] and Burkholderia
pseudomallei (burkavidin) [12]. Avidins are known to be homotetra-
metric proteins, with the exception rhizavidin, which is a
homodimer in its native form [11]. Due to the high-affinity
interaction with D-biotin, avidins are widely applied in life sciences
as well as in bio- and nanotechnology [13–15].
The best-studied avidins are the mature forms of chicken avidin
and streptavidin. In the chicken egg-white, only the 28 amino acid
signal peptide is removed from the full-length polypeptide chain to
form the mature avidin protein (residues 1–128) [1], whereas
several different cleavage products have been detected for
streptavidin [16]. Streptavidin has been expressed as a recombi-
nant protein with and without signal peptide [17,18]. The most
stable truncated form of streptavidin is the so-called core
streptavidin, which contains residues 13–139 but still retains
extremely high affinity towards D-biotin Kd ,10–15 M [16]. Full-
length wild-type (wt) streptavidin is expressed as a polypeptide of
159 residues. Interestingly, C-terminal residues 150–153 (Asn150-
Gly151-Asn152-Pro153) of wt streptavidin fold back into the
biotin-binding site in each monomer [19], thereby competing with
the binding of at least low-affinity biotinylated macromolecules
[16,20].
Bradavidin is a tetrameric biotin-binding protein structurally
and functionally resembling chicken avidin and other avidins. The
gene encoding bradavidin was identified in B. japonicum, a nitrogen
fixing and root nodule-forming symbiotic bacterium of the
soybean [9]. Full-length, wt bradavidin has 138 amino acid
residues, whereas the C-terminally truncated core form (core-
bradavidin) has 118 amino acid residues [9]. Although bradavidin
shares structural and functional similarities with other avidins, the
percentage of amino acid sequence identity between the core
regions of bradavidin and chicken avidin or streptavidin is only
about 30%. As an additional indication of uniqueness, bradavidin
has been proven to be immunologically different from chicken
avidin and streptavidin [9]. Moreover, bradavidin has an acidic pI
value (6.3 for wt bradavidin and 4.1 for core-bradavidin [9])
whereas mature chicken avidin (pI,10 [1]) is a basic protein. This
property may allow the use of bradavidin instead of chicken avidin
in applications disturbed by the charge-driven, non-specific
binding of chicken avidin [21,22].
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In this study, we have determined the crystal structure of full-
length, wt bradavidin at 1.8 A˚ resolution. Inspired by the X-ray
structure, C-terminal residues occupying the biotin-binding pocket
of wt bradavidin were evaluated as an affinity tag (Brad-tag) by
using a synthetic peptide and by producing a fusion protein of
enhanced green fluorescent protein (EGFP) and the Brad-tag. The
binding of Brad-tag to core-bradavidin and other biotin-binding
proteins were characterized using isothermal titration calorimetry
(ITC) and its effect on the stability of bradavidin was determined
by differential scanning calorimetry (DSC).
Results
The X-ray Structure of Bradavidin Reveals Unique
Features
Wild-type bradavidin and core-bradavidin were produced in the
periplasmic space of E. coli in an active form, essentially as
previously described [9]. Bottle cultures (typical protein yields were
around 1–5 mg/L) and a pilot-scale fermentor (yields of 3–7 mg/
L) were used for protein expression. The isolated proteins were
homogeneous and of high purity by SDS-PAGE analysis (data not
shown).
In order to help understand the molecular details behind the
functional properties of bradavidin, the 3D structure of wt
bradavidin was solved. We tried to crystallize wt bradavidin in
the absence and presence of biotin, and in the presence of an azo
dye HABA (4-hydroxyazobenzene-2-carboxylic acid, also called 2-
(49-hydroxybenzene)azobenzoic acid) in the hope that the dye
would bind to the biotin-binding site. However, the protein
crystallized only in the presence of HABA, but we could not
identify HABA in the final structure. Orthorhombic crystals with a
homotetramer in the asymmetric unit were obtained (for structure
determination details, see Table 1). Each subunit I-IV (numbering
according to [23]) of wt bradavidin had the overall b-barrel shape
typical of avidins. A long C-terminal tail protruded from the
closed-ends of the barrels and extended into the ligand-binding
sites of the neighbouring subunits, serving as an intrinsic,
intersubunit ligand (named Brad-tag; see below). More specifically,
C-terminal residues of subunit I bound within the biotin-binding
pocket of subunit III (and vice versa), and similar reciprocal
interactions took place between subunits II and IV. These
interactions uniquely anchored the ‘two dimers’ of the tetramer
(a dimer of dimers) to each other (Figure 1A). This kind of
intersubunit interaction has not been reported for any known
member of the avidin family and thus provides an example of the
utilization of an oligopeptide from adjacent subunits as an intrinsic
ligand. In the X-ray structure of the T7-tagged wt streptavidin, C-
terminal residues 150–153 also occupy the biotin-binding site [19],
however, the extended C-terminus and the ligand-binding pocket
into which it folds is formed by a single polypeptide chain
(intrasubunit ligand). The overall intrinsic ligand-binding archi-
tecture is therefore clearly different in bradavidin and in
streptavidin (Figure 1).
Even though the quaternary structure of wt bradavidin
resembles the known structures of avidins (Figure 1A), some of
the secondary structure elements and loops, especially those in the
close proximity to either the N- or C-terminal residues, differ
noticeably in comparison to other avidins (Figures 1B, 1C, 2). For
example, the first five amino acids of wt bradavidin have different
spatial locations in comparison to wt streptavidin or chicken
avidin. Residue Trp5 of bradavidin is located in a key position and
helps determine the unique conformation of the N-terminus: the
Trp5 side chain is located in a hydrophobic pocket created by
residues that include Val3, Trp7, Ile17, Ile27, Leu51, Phe20,
Leu118 and Leu119; the side-chain nitrogen atom of Trp5 is
hydrogen bonded to the carbonyl oxygen of Asp115, too. Residues
1–3 of wt bradavidin interact with residues 17–20 of the b2-strand
and the adjacent L2,3-loop. Additionally, the side-chain oxygen
atom of Asn4 is hydrogen bonded to the backbone nitrogen atom
of Asp115, located at the beginning of the C-terminal extension.
Unique structural features of the C-terminus of wt bradavidin are
seen beginning with residues directly following b-strand 8, and
extending through the adjacent short 3/10-helix and then turning
towards and entering the neighbouring subunit (Figure 1D).
Ala128 and Gly129 are the first residues clearly leaving the
original subunit and form a linker between the original (e.g.
subunit I) and the neighbouring subunit (e.g. subunit III), whereas
the terminal residues 130–138 are part of the neighbouring
subunit. Together, the N- and C-terminal residues have a clear
effect on determining the shape of the fold of wt bradavidin. In
bradavidin, the L4,5-loop and the L6,7-loop of one subunit seem
to be adapted to pack and guide the C-terminal extension towards
the neighbouring subunit and the L7,8-loop of neighbouring
subunit contributes to the conformation of the C-terminus, too
(Figure 1D). Several of the b-strands, i.e. strands 1, 6 and 8, also
differ in their spatial arrangements (length and/or orientation) in
comparison to chicken avidin and streptavidin. Moreover, analysis
of the surface of the bradavidin structure identified bradavidin-
specific characteristics (Figure S1).
Subunit Interfaces of Bradavidin
In a previous study we found that bradavidin in the presence of
biotin was structurally less stable when compared to either chicken
avidin or streptavidin [9]. Avidins gain stability via oligomerization
[24,25] and the subunit-interfaces play a significant role in
determining their stability. Consequently, the subunit-subunit
contacts of bradavidin were carefully examined.
Four tyrosine residues (Tyr90), one from each subunit, are
located in the center of the bradavidin tetramer (Figure 3), and
they are likely to play a major role in the assembly and stability of
the tetramer. Structural water molecules in the vicinity (2.6–2.8 A˚)
of the hydroxyl groups support the idea that hydrogen bonds
together with ring stacking stabilize the tetramer.
In bradavidin, there are eight residues (Trp89, Tyr90, Leu91,
Trp99, Asn100, Ile102, Ser103 and Ala104) having non-hydrogen
atoms within 4 A˚ of each other at the interface of subunits I and II.
Ile102, Ser103 and Ala104 form the core of the I-II interface and,
together with Tyr90 and Asn100, are the most characteristic
residues of the I-II subunit interface (Figure S2). Of these residues,
only an isoleucine equivalent to Ile102 of bradavidin is found in
one other known avidin structure, rhizavidin [11]. Interactions
among residues (102–104) of the I-II interface include conven-
tional hydrogen bonds between the backbone oxygen atom of
Ile102 and the backbone nitrogen atom of Ala104– these
backbone interactions are well conserved within the avidin family.
A weak hydrogen bond (C-H…O; [26,27]) between the side-chain
oxygen atom of Ser103 and the Ca atom of Asn100 was also seen.
Moreover, the Cg atom of Trp89 is at a distance of 3.6 A˚, and
thus able to form a weak hydrogen bond (C–H…O) with the
backbone oxygen atom of Trp99. Both Trp89 and Trp99 are well
conserved within the avidin family, including chicken avidin and
streptavidin, and are known to line the biotin-binding pocket.
Leu91 of bradavidin is also well conserved and its side chain is
involved in van der Waals interactions with the side chain of
Trp99. The side chain of Tyr90 is in van der Waals contact with
the side-chain atom of Ala104.
The core of the I-III subunit interface of wt bradavidin is
formed by Gln86, Leu88, Tyr90, Ala104 and Ala106 (Figure S2),
Structure of Bradavidin
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which are all poorly conserved in the avidin family. For example,
Gln86, Leu88, Tyr90, Ala104 and Ala106 in bradavidin are in
chicken avidin (and streptavidin) Lys94 (Asn105), Met96 (Gln107),
Leu98 (Leu109), Val115 (Val125) and Ile117 (His127). The
nitrogen atom of the Gln86 side chain of subunit I is hydrogen
bonded with the carbonyl oxygen atom of Ala106 of subunit III
(and vice versa), and the Cb atoms of Ala106 of subunits I and III
are in van der Waals contact with each other. Weak van der Waals
interactions between the side chain of Leu88 and the atoms of
Ala104 are apparent, too. Tyr90 of subunit I is within hydrogen-
bonding distance (2.8 A˚) of Tyr90 of subunit III. The C-terminal
residues 129–137, containing the residues of the Brad-tag, are also
involved in I-III subunit interactions but these residues are
described separately below.
The I-IV subunit interface of bradavidin involves 47 amino acid
residues (4 A˚ probe using non-hydrogen atoms) and is stabilized by
a large number of non-covalent interactions. In comparison to
known avidin structures, the I–IV subunit interface of bradavidin
is also distinctive. In addition to the central Tyr90 and the C-
terminal Brad-tag, the I–IV subunit interface is stabilized by van
der Waals interactions and hydrogen bonding of e.g. the side chain
of Trp50 with the atoms of residues Gly46, Thr48, Ser63, Val64
and Asn65, and the side chain of the well-conserved Gln78 is
uniquely packed against residues of the L7,8-loop, and Trp99 of
this loop is part of the ligand-binding site.
All in all, tetrameric wt bradavidin is stabilized by a large set of
non-covalent intersubunit interactions, many of which are unique
to bradavidin within the members of the avidin family. However,
the decreased thermal stability of bradavidin suggests that the
subunit interfaces of wt bradavidin are less optimal for maintaining
the tetrameric stability as in chicken avidin or streptavidin.
The Ligand-binding Site of wt Bradavidin has an Intrinsic
Ligand
The C-terminal extension of each subunit in wt bradavidin
reaches out and occupies the ligand-binding site of an adjacent
subunit, serving as an intrinsic, intersubunit ligand. Namely,
residues 130-138 of subunits I and II respectively occupy the
ligand-binding pocket of subunits III and IV, and vice versa
(Figure 1). In comparison to chicken avidin [PDB: 1AVD; [28]] or
wt streptavidin [PDB: 2BC3; with a T7-tag], the ligand-binding
site of wt bradavidin is rich in novel features. For example (see
Figure 4A), the C-terminus (Ser130-Lys137) of subunit I has two
consecutive turns mimicking the shape of an S letter (‘‘S-shaped’’)
and embedding between Ser13, Tyr31 and Asn33-Asp40 (L3,4-
loop) of the neighbouring subunit III on one side and, on the other
side, Trp99 of a third subunit (IV). The binding pocket (III) is lined
by Asn9, Tyr11, Phe66, Ser71, Thr73, Trp75, Trp89, Leu91 and
Asp107 and the L3,4-loop is stabilized by an intrasubunit disulfide
bond between Cys39 and Cys69, similar to rhizavidin [29]. In
general, the C-terminus causes the opening or widening of the
ligand-binding pocket of wt bradavidin in a manner not observed
for any other known avidin structure. The binding of the C-
terminal extension of bradavidin is stabilized by a number of non-
covalent interactions and several structural water molecules are
found in close proximity of the binding site (Figure 4A).
Glu131, Lys132 and Leu133 of wt bradavidin insert deepest
into the ligand-binding pocket of the adjacent subunit. When
superimposed with chicken avidin [PDB: 1AVD], it is evident
that residues 131-133 occupy the site equivalent to the biotin-
binding site of avidin (Figure S3). The Leu133 side chain
matches the location of the carboxylate end of biotin, whereas
the side chain of Lys132 fills the space occupied by the bicyclic
ring system (29-keto-3,4-imidazolidotetrahydrothiophene moiety)
Figure 1. Structure comparison of wt bradavidin, wt streptavidin [PDB: 2BC3] and chicken avidin [PDB: 1AVD]. (A) Cartoon models of
tetrameric proteins. Subunits are shown in different colors as follows: I (blue), II (cyan), III (magenta) and IV (yellow). The key biotin-binding pocket
occupying residues (wt bradavidin and wt streptavidin) and biotin (chicken avidin) are shown as spheres. The N- and C-termini are indicated by
letters. (B) Superimposition of the Ca traces of subunits I of wt bradavidin (blue), wt streptavidin (orange) and chicken avidin (cyan). The Ca trace for
C-terminal residues starting from Lys127 of subunit III of wt bradavidin is shown, too. The ligand-binding site occupying residues Glu131-Leu133 of
wt bradavidin and Gly151-Pro153 of wt streptavidin, and the biotin ligand of avidin, are shown as sticks. The left and right arrows pinpoint the N- and
C-terminal sites, respectively, were major differences are seen between the proteins. Trp5 (left arrow) of wt bradavidin is shown as sticks. The N- and
C-termini are indicated and loops are numbered. (C) Monomeric cartoon models. The N-terminus and C-terminus of each protein are indicated in red
and blue, respectively, the colouring starting from equal positions in all proteins. The key residues occupying the biotin-binding site are shown as
sticks. (D) Loop design. Colouring of subunits are as in (A) and representation of the key residues as in (C). The arrow pinpoints the varying
beginnings of the L7,8-loops in the three structures. The L3,4-loop of the wt streptavidin structure is not fully visible (dashed line).
doi:10.1371/journal.pone.0035962.g001
Table 1. X-ray structure determination statistics for wt
bradavidin [PDB: 2Y32].
Cell parameters
Space group P212121
Unit cell:
a, b, c (A˚) 46.7, 84.9, 120.3
a, b, c (u) 90, 90, 90
Data collectiona
Wavelength (A˚) 1.04192
Beamline I911–2 (MAX-lab, Lund)
Detector MarCCD
Resolution (A˚)b 25–1.78 (1.78–1.88)
Unique observationsb 46670 (6955)
I/sigmab 18.0 (5.9)
Rfactor (%)
b 9.0 (42.4)
Completenessb 100 (100)
Redundancyb 9.6 (9.6)
Refinement
Rwork (%)
c 14.4
Rfree (%)
c 18.2
Monomers (asymmetric unit) 4
Protein atoms 4115
Solvent atoms 680
R.m.s.d:
Bond lengths (A˚) 0.014
Bond angles (u) 1.4
aThe numbers in parenthesis refer to the highest resolution bin.
bFrom XDS [53].
cFrom Refmac 5 [57] using TLS [71] & restrained refinement.
doi:10.1371/journal.pone.0035962.t001
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of biotin. Glu131 stabilizes the local structure, and especially,
the side-chain conformation of Lys132 (Figure S4). With respect
to the wt streptavidin structure [PDB: 2BC3], Leu133
superposes with Pro153, whereas the side chain of Lys132
overlaps with Gly151. Even though some of the residues lining
the ligand-binding site of bradavidin, avidin and streptavidin are
identical in sequence and are structurally conserved (Figure 4B),
the binding mode of Glu131-Lys132-Leu133 is different from
that seen for Gly151-Asn152-Pro153 in the wt streptavidin
structure and for biotin in the avidin structure (Figures 4, S3).
This is due to the two-layered, ‘‘S-shaped’’ conformation of the
C-terminus of bradavidin, the terminus entering into a
neighbouring subunit (Figures 1, 4). Moreover, the side-chain
nitrogen atom of K132 is stabilized by several hydrogen bonds;
interaction of K132 (NZ atom) with the side-chain oxygen
atoms of Y31, D107 and E131 are possible; Y31 and D107 are
from a different subunit (Figure S4).
To get an idea how biotin would bind to the presumed ligand-
binding site of wt bradavidin and how it would affect to the
conformation of the C-terminus, we tried to co-crystallize wt
bradavidin with biotin. However, we did not get any crystals
with biotin. Therefore, selected residues lining the biotin-binding
site of chicken avidin [PDB: 1AVD] were superimposed with the
equivalent residues of wt bradavidin (Figure 4B). We left out the
C-terminal residues (Brad-tag) of wt bradavidin from the
structural comparison because of two reasons: 1) the C-terminus
is very likely to undergo major conformational changes due to
biotin binding, changes that would require heavy computations
to give reasonable predictions (beyond this study); and 2) direct
contacts between the C-terminal residues and biotin are not
likely to occur. Our structural comparison suggests that the L3,4-
loop of wt bradavidin, and especially the residues Ala35-Ser38 of
it, should undergo a major conformational change for efficient
biotin binding, whereas most of the other residues (i.e. not in the
L3,4-loop) lining the presumed biotin-binding site of wt
bradavidin have conformations close to those seen in chicken
avidin and are hence likely to undergo only minor conforma-
tional changes due to biotin binding. In conclusion, most of the
Figure 2. Sequence alignment of wt bradavidin, rhodavidin, streptavidin and chicken avidin. The UniProt [70] accession numbers are
shown after the names of the sequences. The Brad-tag sequence is highlighted with orange background, cysteine residues with yellow and the
tryptophan residue important for the N-terminus of wt bradavidin with cyan. The secondary structures of wt bradavidin (from the structure reported
here) and chicken avidin (from [PDB: 1AVD]) are shown. The truncation site for core-bradavidin is between Leu118 and Leu119 and is shown by a
short, vertical dashed line. The conserved residues are indicated by the default colouring scheme of the ESPript program. TT, b-turn; TTT, a-turn; and
g1, 3/10-helix. The structural alignment was created in Bodil [66] and the picture using ESPript [68].
doi:10.1371/journal.pone.0035962.g002
Figure 3. Four tyrosine residues at the intersection of all four subunit interfaces in bradavidin. A stereo view. The tyrosine residues are
shown as stick models with different colouring for the different subunits (subunit I, blue; II, cyan; III, magenta; and IV, yellow). Structural water
molecules are shown as red spheres. Electron density map (a weighted 2FO-FC map; sigma level 1) around the water molecules and the side chain
oxygen atoms of Tyr90 is shown in blue. Putative hydrogen bonds are indicated with grey dashes.
doi:10.1371/journal.pone.0035962.g003
Structure of Bradavidin
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Figure 4. Stick model (stereo view) of the ligand-binding site of wt bradavidin. (A) The carbon atoms of the Brad-tag sequence (subunit I)
are shown in blue and the residues around the Brad-tag sequence in magenta (subunit III) and yellow (subunit IV). Structural water molecules near
the Brad-tag sequence are shown as red spheres. (B) Superimpositioning of the ligand-binding site of wt bradavidin and chicken avidin [PDB: 1AVD].
Colouring for wt bradavidin as in (A); the carbon atoms of residues of chicken avidin are shown in grey. The residues Asn12, Leu14, Ser16, Tyr33,
Trp70, Ser73, Ser75, Thr77, Phe79, Trp97, Leu99 and Asn118 of chicken avidin were superimposed to the equivalent residues Asn9, Tyr11, Ser13,
Structure of Bradavidin
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interactions seen between chicken avidin and biotin [PDB:
1AVD] are probably also seen in wt bradavidin when in complex
with biotin.
Several peptide tags binding to the biotin-binding site of avidin,
and particularly to streptavidin, have been reported (Table 2), and
X-ray structures are known for the Strep-tag [PDB: 1RST], Strep-
tagII [PDB: 1RSU, 1KL3/5] and Nano-tag [PDB: 2G5L]
streptavidin complexes. However, the binding modes of these tags
are clearly different from that seen for bradavidin (Figure S5). For
example, the peptide backbone of Strep-tag [30], Strept-tag II
[30,31] and Nano-tag [32] have a 310-helical conformation,
whereas the C-terminus of wt bradavidin is a combination of two
consecutive turns.
Isothermal Titration Calorimetry Reveals Moderate
Affinity between Brad-tag and Core-bradavidin
We used isothermal titration calorimetry (ITC) to determine
the affinity between core-bradavidin and a synthetically
produced Brad-tag (SEKLSNTK), and found that the binding
enthalpy of Brad-tag to core-bradavidin was temperature
dependent (Figure 5, Table 3). At 15uC, the enthalpy was
found to be positive (1.160.2 kcal/mol, Figure 5A1) indicating
endothermic binding, whereas a negative binding enthalpy
(–4.460.3 kcal/mol, Figure 5C1) was observed for core-brada-
vidin titrated with Brad-tag at 40uC, indicating the exothermic
nature of binding. At 25uC, the binding enthalpy was negligible
(Figure 5B1) most likely because the measurement was
performed close to the transition temperature between the
exothermic and endothermic binding mode. The calculated
dissociation constant (Kd) was 25 mM at 15uC and 26 mM at
40uC but could not be determined at 25uC.
We could not determine the Kd of D-biotin for core-bradavidin,
as the measurement exceeded the sensitivity limit of ITC (Kd ,10
–9
M). However, ITC titration provided the enthalpy and stoichiom-
etry of the binding. The highly negative binding enthalpies (–
15.960.1, –20.160.1, and –26.460.1 kcal/mol at 15, 25 and
40uC, Figures 5A3, B3, C3, respectively) indicated the exothermic
nature of biotin binding and were in accordance with our earlier
observations with rhizavidin [11] and avidin [33]. The average of
the calculated stoichiometries of binding at different temperatures
was 0.7860.23/subunit, suggesting 1:1 binding of Brad-tag to core-
bradavidin subunits. In a competitive binding assay, core-
bradavidin was first saturated with Brad-tag followed by a second
titration with biotin (Figures 5A2, B2, C2). At 15uC, the measured
enthalpy (–17.360.1 kcal/mol) was more negative in the compet-
itive binding assay than in the non-competitive assay, because core-
bradavidin was saturated with Brad-tag (positive enthalpy) before
titration with biotin (Figure 5D). At 25uC, the enthalpies for
competitive and non-competitive binding of biotin differed only by
0.4 kcal/mol; the enthalpy measured for the binding of Brad-tag to
core-bradavidin was close to zero at this temperature. At 40uC, the
competitive biotin titration resulted in less negative enthalpy (–
21.460.1 kcal/mol) than the non-competitive binding. The sum of
the measured binding enthalpy of core-bradavidin titrated with
Brad-tag and the enthalpy of the competitive titration with biotin
was almost equal to the binding enthalpy of core-bradavidin titrated
with biotin only.
Avidin, streptavidin and rhizavidin were titrated with Brad-tag
at 40uC (Figure S6) in order to study the specificity of Brad-tag
towards core-bradavidin. No sign of interaction was observed,
indicating that Brad-tag is specific for core-bradavidin.
Tyr31, Phe66, Cys69, Ser71, Thr73, Trp75, Trp89, Leu91 and Asp107 of wt bradavidin. For clarity, the Brad-tag sequence is not shown. For chicken
avidin, the residue numbers are shown in brackets. BTN, biotin; *, Tyr31 (Tyr33); **, Asn33 (Thr35).
doi:10.1371/journal.pone.0035962.g004
Table 2. Summary of different avidin-binding peptide tags.
Tag
Sequence
(residues)
Size
(kDa) Receptor Kd
PDB
entry References
Avi-tag DRATPY (6) 0.72 Avidin,
NeutrAvidin
28 mM
12 mM
a [72]
AviD-tag Divalent DRATPY
(6+spacer+6)
1.44+spacer Avidin,
NeutrAvidin
a a [73]
Nano-tag15 fMDVEAWLGAR
VPLVET
(formyl-Met+15)
1.81 Streptavidin 4 nM a [74]
Nano-tag9 fMDVEAWLGAR (formyl-Met+9) 1.18 Streptavidin 17 nM a [74]
Nano-tag fMDVEAWL
(formyl-Met+6)
0.89 Streptavidin ,20 nM 2G5L [32]
Strep-tag AWRHPQFGG (9) 1.06 Streptavidin 37 mM 1RST [30]
Strep-tag II WSHPQFEK (8) 1.06 Streptavidin
SA mutant 1 i.e.
StrepTactin
SA mutant 2
72 mM
1 mM
1 mM
1RSU 1KL3
1KL5
[30,31,75]
SBP-tag MDEKTTGWRG
GHVVEGLAGE
LEQLRARLEH
HPQGQREP (38)
4.31 Streptavidin 2.5 nM a [76]
Brad-tag SEKLSNTK (8) 0.91 Core-bradavidin 25 mM This study
aNot available.
doi:10.1371/journal.pone.0035962.t002
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Figure 5. ITC analysis of ligand binding. Thermograms of measurements performed at three different temperatures (A) 15uC, (B) 25uC and (C)
40uC are shown. At each temperature, core-bradavidin was first titrated with Brad-tag (1), followed by competitive titration with biotin (2). As a
control measurement, core-bradavidin was titrated with biotin only (3). In order to prove that the intrinsic Brad-tag decreases the affinity towards
biotin, wt bradavidin was also titrated with biotin (4). In addition, core-bradavidin was titrated with Brad-tag–EGFP at 15 and 25uC (5). (D) Comparison
of the binding enthalpies of all measurements at different temperatures. Brad-tag had a clear effect on the binding enthalpy of the competitive
titration with biotin at 15uC (endothermic Brad-tag binding) and 40uC (exothermic Brad-tag binding). At 25uC, the enthalpy of competitive titration
was equal to that of titration with biotin only (no detectable binding of Brad-tag to core-bradavidin).
doi:10.1371/journal.pone.0035962.g005
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C-terminal Extension Stabilizes wt Bradavidin and Inhibits
Biotin Binding
ITC analysis revealed a clearly reduced biotin-binding affinity for
wt bradavidin (Kd ,2.8610–7 M) compared to core-bradavidin (Kd
,10–9 M) (Figure 5, Table 3). This indicates that the C-terminal
extension of bradavidin competes with biotin for the ligand-binding
site, which is in agreement with the structure of wt bradavidin. The
exothermic binding was detected as highly negative enthalpies (–
16.860.2, –15.560.1, and –13.760.2 kcal/mol at 15, 25 and 40uC;
Figures 5A4, B4, C4, respectively). At 40uC, we observed a two-phase
binding-curve and the non-linear least-squares fit was not perfect
over the first three titration steps, increasing the error in the binding
enthalpy. One possible explanation for this could be that the C-
terminus becomes more flexible at 40uC due to increased thermal
motion.
Differential scanning calorimetry (DSC) was used to study the
heat-induced unfolding of core-bradavidin and wt bradavidin. The
melting temperatures (Tm) for core-bradavidin in the absence and
in the presence of biotin were 73.260.3uC and 97.960.2uC. For
wt bradavidin, the Tm value without biotin was 96.260.1uC, and
101.760.1uC with biotin. These results further indicate that the
C-terminal extension (including the Brad-tag) can serve as an
intrinsic ligand and stabilize wt bradavidin, since the melting
temperatures of wt bradavidin with and without biotin were quite
similar. No peaks were seen in the second heating scan of DSC
analysis, indicating irreversible unfolding, which is typical for
avidin proteins.
Feasibility of Brad-tag as Affinity Tag
In order to study the potential of Brad-tag as an affinity tag, we
designed four different fusion proteins with EGFP as described in
Figure 6A. The recombinant Brad-tag–EGFP fusion proteins were
produced in E. coli and their expression was analyzed by
immunoblotting, where Brad-tag–EGFP and Brad-tag–EGFP–
His-tag were clearly recognized by an antibody against GFP
(Figure 6B). In contrast, the signal from C-terminally tagged
EGFPs was negligible, indicating that proteins were not produced
efficiently. Shorter protein forms were also seen in the lysates
corresponding to C-terminally tagged EGFPs, possibly resulting
from proteolytic cleavage. The spectrofluorometric analysis of
cellular lysates, however, confirmed that the C-terminally tagged
EGFPs were expressed (Figure 6C).
To find out whether the Brad-tag would prove functional in
protein purification, core-bradavidin was conjugated to a sephar-
ose resin. As a first experiment, Ni-NTA purified Brad-tag–
EGFP–His-tag fusion protein was loaded onto the core-bradavi-
din-conjugated resin, which concentrated the fusion protein
(Figure 7A). In contrast, a resin saturated previously with free
biotin had no concentrating effect showing that biotin can
efficiently prevent Brad-tag–core-bradavidin interaction. As a
second experiment, we also studied whether Brad-tag–EGFP
could be purified from cleared cellular lysates with core-
bradavidin-conjugated resin. First, cleared cellular lysates were
incubated with resin, and then the resin was washed with the
binding buffer, which quite rapidly (,5–10 column volumes) led
to dissociation of the bound protein. The protocol still made it
possible to separate Brad-tagged EGFP from other proteins of the
Table 3. Thermodynamic parameters of ligand binding analyzed by ITC.
Cell Syringe T DH -TDS DG Kd n
Contents cinitial Contents cinitial
[mM] [mM] [6C] [kcal mol–1] [kcal mol–1] [kcal mol–1] [M]
Core-bradavidin 0.073 Brad-tag 0.985 15 1.760.2 –7.7 –6.1 2.560.5610–5 0.94
Brad-tag/core-
bradavidin
0.169/0.06 Biotin 0.6 15 –17.360.0 NDa NDa ,10–9 0.95
Core-bradavidin 0.01 Biotin 0.1 15 –15.960.1 NDa NDa ,10–9 0.93
Core-bradavidin 0.015 Brad-tag–
EGFP
0.15 15 –0.560.1 –6.8 –7.3 2.860.8610–6 b 0.68 b
wt Bradavidin 0.01 Biotin 0.1 15 –16.860.2 8.1 –8.7 2.760.2610–7 0.61
Core-bradavidin 0.05 Brad-tag 0.25 25 NDc NDc NDc NDc NDc
Brad-tag/core-
bradavidin
0.043/
0.041
Biotin 0.4 25 –20.560.1 NDa NDa ,10–9 0.97
Core-bradavidin 0.05 Biotin 0.5 25 –20.160.1 NDa NDa ,10–9 0.98
Core-bradavidin 0.015 Brad-tag–
EGFP
0.15 25 –1.060.1 –6.5 –7.5 3.161.0610–6 b 0.68 b
wt Bradavidin 0.01 Biotin 0.1 25 –15.560.1 6.6 –8.9 3.060.2610–7 0.85
Core-bradavidin 0.1 Brad-tag 1 40 –4.460.3 –2.2 –6.6 2.660.3610–5 0.62
Brad-tag/core-
bradavidin
0.172/
0.083
Biotin 0.8 40 –21.460.1 NDa NDa ,10–9 0.91
Core-bradavidin 0.01 Biotin 0.1 40 –26.460.1 NDa NDa ,10–9 0.93
wt Bradavidin 0.01 Biotin 0.1 40 –13.760.2 4.3 –9.4 2.660.4610–7 1.08
aKd could not be determined as it exceeded the sensitivity limit of ITC.
bA rough estimate because the noise level in thermogram was relatively high.
cCould not be determined.
doi:10.1371/journal.pone.0035962.t003
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cell lysate as verified by SDS-PAGE (Figure 7B). Moreover, the
emission spectrum of the isolated Brad-tag–EGFP protein strongly
resembled that of free EGFP indicating that the tag did not affect
the conformation of EGFP (Figure 7C).
In order to further study the functionality of Brad-tag, we
performed ITC analysis using Brad-tag–EGFP and core-bradavi-
din. Here, slightly negative binding enthalpies (–0.560.1 at 15uC
and –1.060.1 kcal/mol at 25uC) were detected, indicating
exothermic binding. However, the noise level in the thermograms
(Figures 5A5, B5) was relatively high because of low protein
concentrations, and therefore, the non-linear least-squares fit only
gave a very rough estimate of the Kd : ,3.0610–6 M (Table 3).
Specificity of Brad-tag Binding
The specificity of core-bradavidin binding to Brad-tag was
studied using a biolayer interferometry biosensor ForteBio Octet
RED384. Anti-Penta-HIS biosensors were functionalized with
Brad-tag–EGFP–His-tag fusion protein showing efficient binding
(Figure 8A, shift ,1 nm). The Brad-tag-functionalized sensors
were then incubated in the presence of different avidin proteins. At
a protein concentration of 0.06 mg/ml, only core-bradavidin
showed clear binding to the sensor surface, whereas wt bradavidin,
avidin, streptavidin or rhizavidin were not distinguishable from a
sample with plain buffer (Figure 8A). We noticed dissociation of
Brad-tag–EGFP–His-tag from the sensor surface, and therefore
the buffer sample was subtracted from the other measured data to
better illustrate the binding reaction (Figure 8B).
To further prove the specificity of the binding (Figure S7), we
exposed the Brad-tag–EGFP–His-tag functionalized sensor to
solutions containing higher protein concentrations as follows: core-
bradavidin (0.5 mg/ml), wt bradavidin (1.2 mg/ml), chicken
avidin (1.8 mg/ml), streptavidin (1.7 mg/ml) and rhizavidin
(2.0 mg/ml). Core-bradavidin showed a strong binding response
(shift 1.2 nm, Figure S7A), and chicken avidin showed a small
response (shift 0.13 nm; Figure S7A). However, further control
measurements revealed that chicken avidin bound equally well to
plain anti-Penta-HIS biosensors (shift ,0.35 nm, Figure S7D).
This was not surprising, as avidin is a highly basic protein (pI ,10)
[1], and has in numerous previous studies been shown to bind
non-specifically on different materials. Interestingly though, the
binding of chicken avidin to both sensor types could be inhibited in
the presence of free biotin, which seems to be the case also for
chicken avidin–DNA interaction [34]. Core-bradavidin also
showed some binding to non-functionalized anti-Penta-HIS
sensors (shift ,0.45 nm; Figure S7D), but this binding was not
dependent on the presence of biotin. Importantly, core-bradavidin
showed no binding to the Brad-tag–EGFP–His-tag-functionalized
surface in the presence of biotin (Figure S7C), thus proving the
specificity of the assay. We also confirmed the specificity of the
binding by coating the anti-penta-HIS surface with His-tagged
EYFP (Hyto¨nen, Saeger & Vogel unpublished). Neither core-
bradavidin nor chicken avidin showed binding to this surface (data
not shown).
Discussion
We recently characterized a novel biotin-binding protein from
the symbiotic bacterium B. japonicum, and named the protein
bradavidin. It resembles chicken avidin and streptavidin in terms
of the biotin-binding properties, but has different immunological
properties [9]. This property could be beneficial for development
of clinical applications, where bradavidin could be used instead of
avidin or streptavidin. In the original study, the evaluation of the
biotin-binding properties of bradavidin was carried out by
Figure 6. Brad-tag–EGFP fusion proteins. (A) Four different Brad-
tag–EGFP fusion protein constructs were used in the current study.
Brad-tag was positioned at the N- or C-terminus of the fusion proteins.
A His-tag was also included in two of the constructs directly after the
sequence of EGFP. (B) Immunoblot analysis using antibody against GFP
was used to evaluate the quality and amount of tagged EGFPs.
Biotinylated–EGFP was used as a positive control (Vikholm-Lundin et al,
unpublished) and core-bradavidin as a negative control. Numbers in
brackets indicate different protein productions. Molecular weight
markers (M, kDa) are indicated on the left. (C) The fluorescence spectra
measured for purified Brad-tag–EGFP–His-tag (12.4 ng/ml) and clarified
cellular lysates of other Brad-tag–EGFP constructs.
doi:10.1371/journal.pone.0035962.g006
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measuring the dissociation rate constants (kdiss) of biotin analogues
[9], and the dissociation rate determined at 30uC by radioactive
[3H]-biotin was very similar for core-bradavidin (kdiss 1.9610
24
s21) and wt bradavidin (kdiss 2.9610
–4 s–1), but faster than for
avidin (kdiss 1.3610
–7 s–1, extrapolated from the data published in
[35]) and streptavidin (kdiss 9.0610
–6 s–1 extrapolated from the data
published in [36]). In contrast, at 50uC, both core-bradavidin and
wt bradavidin were just as extreme fluorescent biotin conjugate
binders as streptavidin, whereas avidin showed a clearly faster
dissociation rate [9]. These experiments led to the conclusion that
bradavidin and core-bradavidin do not significantly differ in their
ligand-binding properties. However, recent experiments with
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
(DOTA)-conjugated biotin revealed a much lower binding affinity
for wt bradavidin in comparison to core-bradavidin (Hyto¨nen and
Petronzelli, unpublished results).
In the current study, we solved the X-ray structure of wt
bradavidin in order to better understand the function of the full-
length protein at structural level. We also conducted ITC
experiments both with wt bradavidin and core-bradavidin, which
indeed did reveal the lower affinity of wt bradavidin towards biotin
in comparison to core-bradavidin. These findings complete our
understanding of the ligand-binding properties of wt bradavidin,
showing that the C-terminal extension lowers the association rate
of the ligand, whereas the extension has no important effect for the
dissociation phase, at least in the case of biotin and fluorescently-
labelled biotin (Bf560-biotin) [9].
Wt bradavidin has a b-barrel fold typical for avidins. The
overall structure of wt bradavidin revealed clear similarities to the
known structures of avidins but also unique structural features like
the C-terminal extension (see below) and the four Tyr90 residues
packing tightly to each other in the center of the tetramer.
Tyrosine residues are also found in the subunit interfaces of some
known avidin structures, for example in the subunit I-III interface
of the AVR4/5 structure [37], but not in the center of the tetramer
as in bradavidin (Figure 3). Many of the loops and b-strands of
bradavidin also have distinctive structural properties, such as
conformation or length. This is especially true for the b-strands
and loops near or in contact with the termini of the protein
(Figure 1).
Wt bradavidin was crystallized in the presence of HABA, but
the azo-dye ligand was not present in the final structure. Instead,
the C-terminal amino acids Ser130-Lys137 of each subunit of wt
bradavidin folded into the ligand-binding site of the neighbouring
subunit (Figure 1). The C-terminal amino acids (SEKLSNTK)
were named ‘‘Brad-tag’’ and the affinity of this peptide to core-
bradavidin and to other avidins was measured using ITC. We
found that Brad-tag binds to core-bradavidin with an affinity
(,25 mM) comparable to that measured between the original
Strep-tag and streptavidin [30] (Table 2). Similarly to the binding
of other known peptide tags to different avidins (Table 2), the
Figure 7. Purification of EGFP fusion protein using N-terminal Brad-tag. (A) Photograph of Brad-tag–EGFP–His-tag bound to core-
bradavidin resin under UV-light. First, core-bradavidin was coupled by amine groups to the terminal NHS carboxylates of the linkers (resin–NH–
(CH2)5–COONHS). Then, Brad-tag–EGFP–His-tag (prepurified with Ni-NTA column) was incubated with the functionalized resin and the resin was
pelleted. In the absence (–) of biotin Brad-tag–EGFP–His-tag concentrates on the resin pellet. The presence (+) of free biotin inhibits the binding.
Stoichiometry and the size of compounds in the schematic figure are only speculative. (B) SDS-PAGE analysis of the protein purification experiment
for cellular lysates of N-Brad-tag–EGFP-C. Cleared cellular lysate (total) was incubated with core-bradavidin resin. Then the resin was washed with
buffer (50 mM Tris-HCl, 100 mM NaCl, pH 7.5) and samples 1 to 5 were eluted. Molecular weight markers (M, kDa) are indicated on the left. (C) The
fluorescence spectra measured for cleared cellular lysate (total) and eluted samples 1 to 5 from the protein purification experiment for Brad-tag–
EGFP.
doi:10.1371/journal.pone.0035962.g007
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binding of Brad-tag, according to ITC and biosensor analysis,
was specific for bradavidin. In ITC analysis, Brad-tag did not
interact with other biotin-binding proteins that were analysed,
including chicken avidin, streptavidin and rhizavidin. Biosensor
analysis initially showed that chicken avidin may have some
affinity for surface-immobilized Brad-tagged EGFP. However,
our control experiments suggest that this interaction is likely to
be non-specific, typical for highly basic avidin. In order to
demonstrate that Brad-tag could find use in biotechnological
applications, we showed that Brad-tag could be used to
concentrate Brad-tag–EGFP protein from cleared cellular lysate.
However, the affinity is not yet high enough for efficient
purification of fusion proteins and needs to be improved by using
mutagenesis or other methods. In our opinion, Brad-tag has
potential to be an additional tool within the avidin-biotin
technology platform, resembling e.g. Strep-tag [38], a peptide
that binds to the ligand-binding site of streptavidin, and Strep-tag
II that binds with higher affinity (Kd < 1 mM) to an engineered
version of streptavidin (streptactin [18]; Table 2).
Figure 8. Specificity of core-bradavidin binding to Brad-tag analyzed by biolayer interferometry. (A) Anti-Penta-HIS biosensors were
functionalized with Brad-tag–EGFP–His-tag fusion protein (step 1, arrow in the graph). After a brief wash (10 s) in measurement buffer, biosensors
were incubated with a series of different avidin proteins at concentration of 0.06 mg/ml (step 2). Sample without any avidin protein was used as a
negative control (buffer). Finally, biosensors were exposed to the measurement buffer leading to dissociation of the bound core-bradavidin proteins
(step 3). (B) The measured raw data for buffer is subtracted from the raw data of different proteins.
doi:10.1371/journal.pone.0035962.g008
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Our preliminary amino acid sequence comparison of wt
bradavidin and its homolog from Rhodopseudomonas palustris
(Q21816; named rhodavidin [39]) revealed that Trp5, important
for the unique conformation of the N-terminus of wt bradavidin, is
found at an equivalent position in the sequence of rhodavidin. The
high overall similarity for these two proteins (76% sequence
identity; Figure 2) indicates potentially similar tertiary structures.
More interestingly, the C-terminal Brad-tag sequence
(GSEKLSNTK) was found at the C-terminus of rhodavidin but
not, to our knowledge, in any other known sequence of the avidin
protein family. This suggests a similar mechanism for bradavidin
and rhodavidin for the use of the Brad-tag sequence and the
question arises as to the biological significance of this sequence.
Unfortunately, this is not known yet, although it is clear from our
results that the C-terminal extension especially affects the binding
of large biotinylated ligands. It has earlier been suggested that the
C-terminal residues of the T7-tagged wt streptavidin would
compete with weakly bound ligands for the binding site, not least
for the reason that the local concentrations of the intrinsic ligands
are high [16,19,20]. Analogously to wt bradavidin and wt
streptavidin, the C-terminal residues of rhodavidin most probably
also contribute to the ligand-binding preferences. Because of the
much lower affinity for large biotinylated ligands, such as the
endogenous biotin carboxyl carrier protein, one could speculate
that the biological role of both bradavidin and rhodavidin could be
to selectively bind free biotin and, hence, protect the cellular
machinery of the host cell. One could also envision the utilization
of the ligand-binding preferences of wt bradavidin in biochemical
assays.
Even though the biological role of the extended C-termini of wt
bradavidin and wt streptavidin may be the same, the structural
implementation differs: in wt bradavidin each C-terminus reaches
and interacts with the biotin-binding site of the neighbouring
subunit (intrinsic, intersubunit ligand), whereas in T7-tagged wt
streptavidin the C-terminus interact with the ligand binding site of
the same subunit (intrinsic, intrasubunit ligand). The binding
mode of the C-termini of wt bradavidin and T7-tagged wt
streptavidin is different, too. In wt bradavidin, the key residues for
binding to the biotin-binding site are Glu131, Lys132 and Leu133,
whereas those of wt streptavidin are Gly151, Asn152 and Pro153
[19]. Moreover, the T7-tag replaces the 13 N-terminal residues of
wt streptavidin but no electron density was observed for the tag in
the crystal structure [PDB: 2BC3]. Hence, the role of the N-
terminus for the structure of wt streptavidin is not fully clear.
However, the structure of wt bradavidin reported here shows that
the very first N-terminal residues are a unique part of the extended
b1-strand; interactions with the first residues after the last b-
strand, the b8-strand, affect the folding of the C-terminus, too
(Figures 1B, 2).
The ITC-determined dissociation constants (Kd) for Brad-tag to
core-bradavidin were 25 mM at 15uC and 26 mM at 40uC. We also
studied the characteristics of the interaction between Brad-tag and
core-bradavidin by biosensor sandwich assay. Even though this
technique was not optimal for accurate determination of the
binding constants due to the leakage of the His-tagged protein
from the surface (Figure 8A), the 1:1 binding model fitted to the
buffer-subtracted data (Figure 8B) yielded a value of Kd in the
micromolar range, which is in good agreement with our ITC-
analysis data (Table 3). All in all, the determined dissociation
constants were of the same order of magnitude as that for the
original Strep-tag to streptavidin (Kd = 37 mM). Although limited,
the strength of the Strep-tag-streptavidin interaction was found to
be sufficient for affinity purification [30]. The Strep-tag was
functional only when attached to the C-terminus of a fusion
partner, whereas Brad-tag was functional only at the N-terminus,
based on findings made for only one protein, namely EGFP. The
terminus-independent affinity tag, Strep-tag II, has also been
reported and was discovered by screening a designed peptide array
of 400 sequences, but the tag showed lower affinity to streptavidin
(Kd< 72 mM) than the original Strep-tag [30]. In order to improve
the affinity of Strep-tag II, Voss & Skerra (1997) subjected
streptavidin to random mutagenesis resulting in increased affinity
(Kd < 1 mM) [18]. Our novel crystal structure of wt bradavidin
provides the basis for improving the Brad-tag–core-bradavidin
pair, for example, to increase the affinity and other binding
properties by rational mutagenesis of core-bradavidin and/or by
redesigning the tag.
Several affinity tags have been developed and are widely used in
recombinant fusion proteins, e.g. to aid protein purification from
crude cell lysates [40,41] or as tools for probing molecular
functions [42]. Affinity tags include a variety of molecules from
polypeptides to proteins [40] and several of them bind to avidin,
neutravidin or streptavidin (summarized in Table 2). Brad-tag and
core-bradavidin utilizing technology would be a valuable addition
to this toolbox. Since each tag-based strategy has both advantages
and disadvantages, there is a constant need to develop alternative
tag-based strategies. These combined with the existing ones may
be needed to develop novel methodologies suitable for studies of
protein complexes and assemblies. For example, one may envision
tagging of several different proteins being an efficient approach to
characterize complicated molecular arrangements, such as focal
adhesions [43]. On the other hand, by creating circular
permutants of bradavidin [44], we could produce bradavidin
mutants that would bind more than one type of ligand
simultaneously. Moreover, layer-by-layer construction of novel
architectures through biological interactions, including avidin-
biotin, is an evolving area in the field of optical and electrochem-
ical biosensing [45], where the Brad-tag–core-bradavidin pair
could also be used.
In summary, wt bradavidin is a unique member of the avidin
protein family having a C-terminal extension, which enters and
occupies the ligand-binding site of the neighbouring subunit. The
isolated binding epitope has potential to be used as an affinity tag
in the field of bio(nano)technology including detection and
purification methods as well as construction of novel biomaterials
for biosensing and other purposes.
Materials and Methods
Protein Expression and Purification
The construction of core-bradavidin and wt bradavidin
containing pBVboostFG vectors is described earlier [9]. For
Brad-tag–EGFP fusion proteins, the pHis–EGFP plasmid [46,
Saeger, Hyto¨nen & Vogel, unpublished] was used as a template in
PCR, and primers contained the Brad-tag sequence (Table S1).
The amplified PCR-products were extracted from an agarose gel
and subcloned into the pET101/D-TOPOH vector according to
the manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA).
All constructs were confirmed by DNA sequencing (ABI PRISM
3100 Genetic Analyzer, Applied Biosystems).
Core-bradavidin and wt bradavidin were produced in the
periplasmic space of E. coli BL21-AI cells (Invitrogen) in an active
form, as previously described in detail [47]. Similarly, Brad-tag–
EGFP fusion proteins were produced in the periplasm of E. coli
BL21 StarTM(DE3) cells (Invitrogen). The pET101/D-based
expression vectors were transformed into E. coli StarTM(DE3) or
BL21-AI cells. Fresh transformants were cultured using an orbital
shaker with continuous shaking at 28uC in Lysogeny broth (LB)
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medium, supplemented with 100 mg/ml ampicillin and 0.1% (w/
v) glucose for core-bradavidin, 7 mg/ml gentamycin and 0.1% (w/
v) glucose for wt bradavidin, and 100 mg/ml ampicillin for Brad-
tag–EGFP fusion proteins. When the culture reached an OD600 of
0.5, the protein expression was induced by adding 1 mM IPTG
(and 0.2% (w/v) L-arabinose for core-bradavidin and wt
bradavidin). For Brad-tag–EGFP fusion proteins, bottle cultivation
was continued overnight at 28uC, and cells were then collected by
centrifugation (4000 g, 10 min, 4uC). For core-bradavidin and wt
bradavidin, the pilot-scale fermentation was made with a Labfors
Infors 3 (Infors HT, Bottmingen, Switzerland), using the pO2
(DO-stat) controlled fed-batch protocol that has been described in
detail elsewhere [48].
Core-bradavidin and wt bradavidin were purified in a single
step using 2-iminobiotin affinity chromatography (Affiland S. A.,
Ans-Liege, Belgium) [49]. First, 50 g of cells (wet weight) pelleted
from E. coli fermentation were suspended in binding buffer
(50 mM Na-carbonate, pH 11, containing 1 M NaCl). The
suspension was homogenized twice using an EmulsiFlex C3
homogenizator (Avestin Inc., Ottawa, Canada) using homoge-
nizing pressure of 15 000–18 000 psi. After this, cell lysates were
centrifuged (15 000 g, 30 min, 4uC). The supernatant was
filtered and the pH was measured, and when necessary, adjusted
to 10.5 using 10 M NaOH. The crude protein mixture was
applied to 2-iminobiotin agarose, which had previously been
equilibrated with the binding buffer. This mixture was incubated
for one hour on a rolling shaker at 4uC with subsequent
centrifugation (3000 g, 10 min, RT) and two washing steps with
the binding buffer. Finally, the agarose was transferred to a
column and the protein was eluted in one ml fractions with
0.1 M acetic acid (pH 3).
Brad-tag–EGFP fusion proteins containing a His-tag were
purified using Ni-NTA metal-affinity chromatography (Qiagen
GmbH, Hilden, Germany). First, cells from 500 ml cultivation
volume were suspended in lysis buffer (50 mM NaH2PO4,
300 mM NaCl, 10 mM imidazole, pH 8). Lysozyme (one mg
per 100 ml) was added and the cells were sonicated for 5 min
(30% duty cycle, 5 s on, 3 s off) on ice. The cellular debris was
pelleted by centrifugation (15 000 g, 30 min, 4uC) and the
supernatant was filtered using a 0.2 mm filter cloth. Ni-NTA
agarose was equilibrated with lysis buffer before mixing with the
cleared cellular lysate. The resulting mixture was incubated on a
rolling shaker for one hour at 4uC. After this, the mixture was
transferred to a column and washed three times with 20 ml of
lysis buffer and again three times with 20 ml of wash buffer
(50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8).
Finally, the protein was eluted in one ml fractions with elution
buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole,
pH 8).
Brad-tag–EGFP fusion proteins without a His-tag were purified
with core-bradavidin agarose (see below). To prepare the clarified
lysate, the cell pellets were suspended in 50 mM Tris-HCl,
100 mM NaCl, pH 7.5. Lysozyme was added to a final
concentration of 10 mg/l and the mixture was sonicated and
filtered similarly as above.
The purity of all proteins was studied by SDS-PAGE. Cell
lysates and eluted proteins were denaturated by heating at 95uC
for ten minutes in SDS-PAGE sample buffer containing a
reducing agent (b-mercaptoethanol). Samples were run on 15%
SDS-PAGE and the gel was stained with Coomassie Brilliant
Blue. The amount of EGFP fusion proteins were further
investigated by immunoblot analysis. Proteins blotted onto
nitrocellulose were detected by incubating with a primary
antibody against GFP (Anti-GFP Epitope Tag Polyclonal
Antibody, Thermo Scientific) at a 1:2000 dilution. This was
followed by incubation with a secondary antibody - alkaline
phosphatase (AP) conjugate (anti-rabbit IgG-AP, Sigma) at a
1:30000 dilution. Finally, AP was reacted with 5-bromo-4-chloro-
3-indolyl phosphate (BCIP) and nitro-blue tetrazolium (NBT) to
yield a coloured precipitate.
The protein concentration was determined with a UV/Vis
spectrophotometer (NanoDrop 1000 Spectrophotometer, Thermo
Scientific, Wilmington, DE, USA) by measuring the absorbance at
280 nm and using an extinction coefficient of 39085 M–1cm–1 for
core-bradavidin and 20525 M–1cm-1 for EGFP fusion proteins
containing Brad-tag and the His-tag.
Purification of Brad-tag–EGFP Fusion Proteins with
Immobilized Core-bradavidin Resin
Core-bradavidin was coupled to NHS-activated resin through
amine coupling. First, 4.5 ml of core-bradavidin (0.93 mg/ml) in
coupling buffer (10 mM NaHCO3, 0.9% NaCl (w/v), pH 7.5) was
coupled to SepharoseTM 4 fast flow, NHS-4FF (Affiland, Lie`ge,
Belgium). Five ml of resin suspended in isopropanol was
centrifuged (3000 g, 10 min, 4uC) and washed twice with 15 ml
of cold distilled water and centrifuged again (3000 g, 10 min, 4uC).
The supernatant was removed and the protein was added to the
resin. The suspension was incubated on a rolling shaker overnight
at 4uC followed by incubation on a rolling shaker for one hour at
room temperature (RT, 2161uC). The resin was then centrifuged
3200 g, 10 min, at RT and the supernatant was removed. The
protein concentration of the supernatant was measured in order to
estimate the amount of resin-bound protein. Next, the resin was
washed three times with 14 ml of 10 mM NaHCO3, 0.9% NaCl
(w/v), pH 7.5, followed by washing three times with 14 ml of PBS
buffer, pH 4.0, and again three times with 14 ml of PBS buffer,
pH 8.0. Finally, the resin was washed once with 14 ml of PBS
buffer, pH 7.4, and stored at 4uC.
Core-bradavidin resin (0.2 ml) was washed with binding buffer
(50 mM Tris-HCl, 100 mM NaCl, pH 7.5). Purified Brad-tag–
EGFP–His-tag or cleared cellular lysate containing Brad-tag–
EGFP was added to the resin and the mixture was incubated on a
rolling shaker for one hour at 4uC. After this, the resin was
transferred to a column and washed ten times with one ml of
binding buffer and again ten times with one ml of wash buffer
(50 mM Tris-HCl, 1 M NaCl, pH 7.5). Finally, the protein was
eluted in one ml fractions with the elution buffer (50 mM Na-
carbonate, 1 M NaCl, pH 11). All fractions were collected and the
sample tubes were photographed under UV-light to visualize the
elution profile. Samples of fractions were analyzed by 15% SDS-
PAGE and the gel stained with Coomassie Brilliant Blue.
To estimate whether the EGFP fusion proteins were concen-
trated on the resin, 100 ml of the core-bradavidin resin was mixed
with 900 ml of binding buffer in the absence and presence of biotin
(77 mM). Then, 100 ml of Brad-tag–EGFP–His-tag fusion protein
(125 mM) was added and samples were incubated using an orbital
shaker with continuous shaking for 10 min. The resin was pelleted
by incubation without shaking for 10 min and the sample tubes
were photographed under UV-light.
EGFP fusion protein expression and purification were verified
by fluorescence. A QuantaMasterTM spectrofluorometer (Photon
Technology International, Inc., Lawrenceville, NJ, USA) was used
to excite the sample at 485 nm and to detect the emission spectra
from 495 nm to 635 nm. The measurements were performed at
RT in 50 mM Tris-HCl, 100 mM NaCl, pH 7.5. The emission
spectrum of the buffer was subtracted as the baseline.
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Crystallization and X-ray Structure Determination of Wild
Type Bradavidin
Suitable conditions for crystallization of bradavidin were found
using the ClassicsTM (Nextal Biotechnology) screen, the vapour
diffusion method and sitting drops (1–2 ml) on 96 well plates
(Corning Inc.). The protein solution (,0.4 mg/ml) contained
50 mM sodium acetate (pH 4). Saturated solution of an azo dye
HABA (,10 mg/ml) was added to the protein solution in 1:10 (v/
v) ratio, respectively, before crystallization. Bar-like crystals of a
typical size of 0.260.0560.05 mm were used for data collection.
The crystals were formed at 22uC using 0.7 ml of well solution
containing 25% (w/v) PEG 4000, 0.17 M ammonium acetate and
0.08 M sodium acetate (pH 4.6), and 0.8 ml of the protein solution.
X-ray diffraction data were collected at the MAX-lab beam line
I911-2 (Lund, Sweden) equipped with a MarCCD detector. The
crystal was cryoprotected by adding 0.7 ml of 4 M sodium formate
to the crystallization drop just prior to flash-freezing in a 100 K
liquid nitrogen stream (Oxford Cryosystem). The collected data
was originally processed with Mosflm (7.0.3) [50] using the
iMosflm (0.6.1) GUI and scaled with Scala of the CCP4 program
suite [51] using the CCP4i GUI [52], and later reprocessed with
XDS [53] (see Table 1 for X-ray structure determination
statistics).
The initial phase information for structure factors was obtained
using the molecular replacement program Phaser [54] within the
CCP4i GUI [52]. Multiple search models and ensembles were
tested before a solution could be found, finally using homology
models as a search ensemble. Shortly, three tetrameric homology
models were produced using Modeller [55] of Discovery Studio
2.1 (Accelrys Software Inc.). A structural alignment (data not
shown) of the core sequence of bradavidin (Uniprot Q89IH6) and
the sequences from X-ray structures of avidin [PDB: 1AVD],
streptavidin [PDB: 1MK5] and xenavidin [PDB: 2UYW],
respectively, was used for modelling. The models (one model per
template structure) were structurally aligned using Pymol [56] and
their N- and C-termini were trimmed based on visual checking of
the models. Monomers of the aligned structures were then used as
a search ensemble in Phaser (two monomers were searched) giving
an initial solution with TFZ = 8.5 and LGG = 80 in space group
P212121. The initial, incomplete dimeric model of bradavidin was
refined using Refmac5 [57] resulting in an Rfactor = 0.513,
Rfree = 0.536 and FOM = 0.297 and then used as a search model
for the next round of Phaser, where two dimers were searched
giving a solution with TFZ = 13.5 and LGG = 246. Refinement of
the solution, i.e. a tetrameric model of bradavidin, resulted in an
Rfactor = 0.449, Rfree = 0.482 and FOM = 0.477. This model was
used then, again, as a search model in Phaser now yielding a
solution with TFZ = 20.7 and LGG = 320. The model was
manually edited/rebuilt using Coot [58] and refined with
Refmac5 (Rfactor = 0.420, Rfree = 0.456 and FOM = 0.546) before
rebuilding the whole structure with ARP/wARP (starting from an
existing model; v. 6.1.1) [59–61], finally giving a model of
bradavidin that could be finished through further cycles of
refinement with Refmac5 and modification/rebuilding with Coot.
Solvent atoms and other non-protein atoms were added to the
model either with the automatic procedure of ARP/wARP or
Coot, or manually in Coot. Few cycles of the refinement in the
middle of the structure building was done also with the software
suite Phenix [62]. We could not solve the structure without the
step-by-step procedure used for molecular replacement described
above.
The final structure of wt bradavidin was validated using the
inbuilt tools of Coot [58], and using MolProbity [63] of the Phenix
software suite [62], before deposition to the Protein Data Bank
[64,65] with PDB entry code 2Y32. The data collection and
structure determination statistics are summarized in Table 1.
Isothermal Titration Calorimetry
The affinity of core-bradavidin towards Brad-tag or D-biotin
was measured by isothermal titration calorimetry (ITC). We also
analyzed binding between wt bradavidin and D-biotin. The
synthetic Brad-tag, SEKLSNTK, was ordered from GenScript
(Piscataway, NJ, USA). The purified core-bradavidin or wt
bradavidin was dialyzed against 50 mM sodium phosphate
(pH 7.0) buffer containing 100 mM NaCl, and Brad-tag and D-
biotin were directly dissolved in the same buffer. Samples were
degassed with stirring for 5 min and heated to a temperature of 0.5
degrees lower than the measurement temperature by MicroCalTM
ThermoVac. The measurements were performed at 15, 25 or
40uC in an isothermal titration calorimetry VP-ITC MicroCalo-
rimeter (GE Healthcare, MicroCal, Northampton, MA, USA)
with 10 ml titration aliquots of ligands (Brad-tag, biotin or Brad-
tag–EGFP–His-tag) in 30 repeated additions at intervals of 200 s
using constant stirring speed 440 rpm. The data were analyzed
with Microcal Origin 7.0 (MicroCal LLC, Northampton, MA,
USA) software. The observed reaction heats were corrected by
subtracting the heat of dilution caused by the titration of the ligand
alone into buffer. Ka, DH and n (stoichiometry per subunit) were
obtained through non-linear least-squares fit of the corrected
reaction heats for each titration step.
Differential Scanning Calorimetry
The unfolding temperatures of core-bradavidin and wt
bradavidin were analyzed by MicroCalTM VP-Capillary DSC
System (GE Healthcare, MicroCal, Northampton, MA, USA).
Before analysis, the samples were dialyzed against 50 mM sodium
phosphate (pH 7.0) buffer containing 100 mM NaCl. The
proteins were then diluted to a final concentration of 15 mM.
Samples were degassed with stirring for 5 min at 20uC by
MicroCalTM ThermoVac. Thermograms were recorded from
20uC to 135uC using scan rate of 120uC/hour. Two parallel
measurements of each sample were analysed and each of them
were scanned twice. The measurements were conducted in the
absence and in the presence of biotin using ,3:1 molar ratio of
biotin:protein subunit. Microcal Origin 7.0 software was used for
data analysis.
Biolayer Interferometry
Specificity of core-bradavidin binding to Brad-tag–EGFP–His-
tag fusion protein was analyzed by biolayer interferometry using
ForteBio Octet RED384 instrument (Forte´Bio, Menlo Park, CA,
USA). The instrument was controlled by using Data Acquisition
7.0 software (Forte´Bio). First, the baseline for anti-Penta-HIS
biosensors (Forte´Bio) in measurement buffer containing 50 mM
sodium phosphate (pH 7.0) and 100 mM NaCl was recorded for
200 s. Then, Brad-tag–EGFP–His-tag (0.03 mg/ml) was attached
to sensors with 400 s incubation. Following a 10-second washing
step in the measurement buffer, the biosensors were moved to a
solution containing core-bradavidin (0.06 mg/ml) for 200 s. As a
control, 0.06 mg/ml solutions of wt bradavidin, avidin, streptavi-
din or rhizavidin were studied. Finally, biosensors were exposed to
the measurement buffer and the dissociation of bound proteins
was measured for 600 s.
The experiment described above was repeated using higher
protein concentrations and a slightly longer incubation times:
Brad-tag–EGFP–His-tag (0.03 mg/ml) was bound to sensors for
700 s. After washing, the biosensors were then used to study
binding of core-bradavidin (0.5 mg/ml), wt bradavidin (1.2 mg/
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ml), avidin (1.8 mg/ml), streptavidin (1.7 mg/ml) and rhizavidin
(2.0 mg/ml) for 200 s. The dissociation of bound proteins in buffer
was followed for 1900 s. As a negative control, Brad-tag–EGFP–
His-tag coated biosensors, prepared as described above, were
incubated in a solution containing core-bradavidin (0.5 mg/ml)
and avidin (1.8 mg/ml) in the presence of biotin (3.2 mM for core-
bradavidin and 13 mM for avidin). Another control experiment
was carried out by using His-tagged EYFP with terminal cysteine
residues (Hyto¨nen, Saeger & Vogel unpublished) for the
functionalization of the anti-penta-HIS sensors, followed by
incubation with various avidins. Yet another control experiment
was carried out where plain anti-penta-HIS biosensors were
exposed to core-bradavidin (0.5 mg/ml) and chicken avidin
(1.8 mg/ml) both in the absence and presence of biotin (3.2 mM
for core-bradavidin and 13 mM for avidin). The measurement
parameters were as follows: measurement temperature 30uC,
stirring speed 1000 rpm and the distance of the tip from the
surface 4 mm. Black 96-well plates (Greiner Bio-One GmbH,
Frickenhausen, Germany) were used for the biosensor analyses,
1:1 Langmuir binding model was fitted to the buffer-subtracted
binding curve by using Data Analysis 7.0 software (Forte´Bio). For
preparation of the graphs, the raw data was exported from the
instrument and processed with MS Excel.
Miscellaneous Methods
The structure-based sequence alignment was done using Malign
of the Bodil software, a modular, multi-platform software package
for biomolecular visualization and modeling [66,67]. ESPript [68]
was used for visualization of the sequence alignment. PyMOL
(The PyMOL Molecular Graphics System, Version 1.3, Schro¨-
dinger, LLC) was used to create all the figures relating to structural
representations. ABPS plugin of PyMOL (MG Lerner and HA
Carlson. APBS plugin for PyMOL, 2006, University of Michigan,
Ann Arbor) was used for electropotential calculations – alternative
rotamers were excluded from the calculations. Inkscape 0.47 [69]
was used to edit the figures related to structural representations.
Supporting Information
Figure S1 Surface properties of wt bradavidin (reported
here [PDB: 2Y32]) and T7-tagged wt streptavidin [PDB:
2BC3]. Electropotential maps were calculated using the APBS
plugin (MG Lerner and HA Carlson, APBS plugin for PyMOL,
2006, University of Michigan, Ann Arbor) of PyMOL (The
PyMOL Molecular Graphics System, Version 1.3, Schro¨dinger,
LLC). Default settings were used and alternative conformers were
excluded from the calculations. The views rotated 90 degrees
around the x-axis (x90) and y-axis (y90) are also shown.
(TIF)
Figure S2 Subunit interfaces of wt bradavidin and
avidin. The subunit I-II interface (A) and subunit I-III interface
(B) for wt bradavidin [PDB: 2Y32] (left) and avidin [PDB: 1VYO]
(right) are shown. The residues participating to the subunit-subunit
interaction are shown as sticks and the carbon atoms coloured as
follow: subunit I, blue; II, cyan; and III, magenta.
(TIF)
Figure S3 Superimposition of the ligand-binding pocket
occupying residues of wt bradavidin and wt streptavidin
[PDB: 2BC3]. Stereo view. A biotin molecule of chicken avidin
structure [PDB: 1AVD] is also shown for the comparison of
equivalent moieties. Stick models are shown with colouring of the
carbon atoms as follows: wt bradavidin, blue; wt streptavidin,
magenta; biotin, white.
(TIF)
Figure S4 Hydrogen bonding of the side chain nitrogen
atom of K132. A stick model (stereo view) is shown. The carbon
atoms of residues from subunit I are shown in blue and from
subunit III in magenta. Electron density map (a weighted 2FO-FC
map; sigma level 1) around the residues is shown in blue and the
putative hydrogen bonds with yellow dashes.
(TIF)
Figure S5 Structural comparison of peptide tags bind-
ing to the ligand-binding site of wt bradavidin and
streptavidin. Carbon atoms of wt bradavidin and streptavidin
are shown in blue and green, respectively. The PDB entry codes
are shown in brackets.
(TIF)
Figure S6 Brad-tag titrations to control proteins by
ITC. Thermograms of measurements performed at 40uC for (A)
avidin, (B) streptavidin and (C) rhizavidin are shown. No
detectable binding of Brad-tag to these proteins is seen.
(TIF)
Figure S7 Interaction between various avidin proteins
and Brad-tag analyzed by biolayer interferometry. (A)
Anti-Penta-HIS biosensors were coated with Brad-tag–EGFP–His-
tag fusion protein (step 1, arrow in the graph). After a brief wash
(10 s) in measurement buffer, biosensors were incubated with a
series of different proteins: core-bradavidin (0.5 mg/ml), wt
bradavidin (1.2 mg/ml), avidin (1.8 mg/ml), streptavidin
(1.7 mg/ml) and rhizavidin (2.0 mg/ml) and a buffer as a control
(step 2). Binding of core-bradavidin was detected and a slight
increase in the signal for avidin as well. Finally, biosensors were
exposed to buffer and the bound proteins started to dissociate (step
3). (B) The measured raw data for buffer is subtracted from the
raw data measured for different proteins. (C) As a control
measurement, core-bradavidin (0.5 mg/ml) and chicken avidin
(1.8 mg/ml) were measured in the presence of biotin (3.2 mM for
core-bradavidin and 13 mM for avidin). The data where the effect
of the used measurement buffer is subtracted is shown. (D) As
another control measurement, core-bradavidin (0.5 mg/ml) and
chicken avidin (1.8 mg/ml) in the absence and presence of biotin
(3.2 mM for core-bradavidin and 13 mM for avidin) were
incubated with plain anti-penta-HIS biosensors.
(TIF)
Table S1 Sequences of primers used in PCR reactions.
(DOC)
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